The adipose tissue (AT) is an endocrine organ that produces adipocytokines (adipokines), able to influence metabolic homeostasis. In the conventional classification, there are two large AT depots, characterized by different paracrine activities: the subcutaneous AT, which would mostly produce cytokines with protective properties against cardiovascular disease; and the visceral AT, responsible for the secretion of cytokines with proinflammatory, prothrombotic, and proatherogenic effects. A third component, the epicardial AT (EAT) is now receiving increasing attention due to its unique anatomical and functional proximity to the myocardium and the coronary arteries. In rodents, the EAT protects the heart from exposure to high levels of free fatty acids, and provides energy to the myocardium under high metabolic demands. The observation that atherosclerotic plaques are more prevalent in regions of coronary arteries surrounded by the EAT, while they tend to be less present in segments penetrating the myocardium (the septal branches and segments under myocardial bridges), has led to the hypothesis of a possible role of the EAT in promoting the development of atherosclerosis through endocrine and paracrine effects, in addition to the role of biomechanical forces affecting transendothelial lipid permeability into the intima. In this article, we review the clinical and molecular evidence linking the EAT and coronary artery disease through a systematic review of the literature. We, here, discuss current diagnostic techniques in evaluating the interaction between EAT and the onset of coronary artery disease and ischaemic heart disease. Finally, we review current knowledge on the underlying mechanisms by which the EAT may affect coronary atherosclerosis, and potential clinical implications of this interaction, making the EAT an attractive target for new therapeutics in cardiovascular disease.
Introduction
According to morphology, the colour appearance on stained immunosections, physiology and embryological origin, three types of human adipose tissues (ATs) are currently described: the white AT (WAT), the brown AT (BAT), and the more recently recognized brown-in-white (brite) or beige AT ( Figure 1) . Being physiologically deputed to store excess dietary energy such as triglycerides, the WAT functions as a whole-body insulator, and an energy reservoir. 1 In fact, the WAT, with a fine integration of endocrine and neuronal stimuli, performs two main metabolic activities: lipogenesis, such as synthesis and storage of free fatty acids (FFAs); and lipolysis, through the hydrolysis and mobilization of stored triglycerides. 2 In adults, the WAT is distributed throughout the body in two main types of depots: the subcutaneous AT (SAT) in the hypodermis; and the visceral AT (VAT), within the abdominal cavity (including intrahepatic, intramuscular, and perirenal depots) and the mediastinum. The mediastinal or intrathoracic AT is classified as epicardial (EAT), paracardial, pericardial (which is epicardial plus paracardial), perivascular (aortic) and intramyocardial adipose tissue. 3 These different types of adipose depots also have different cellular and molecular signatures (as detailed in the Supplementary material online). Overall, the three types of AT constitute an endocrine organ, able to secrete signalling molecules, FFAs, and protein mediators-adipocytokines (adipokines)-that affect endothelial functions and the metabolic homeostasis. 4 An increasing body of evidence demonstrated that the AT location plays a key role in the type of secreted mediators, mostly adipokines, being the visceral AT, in particular the VAT, associated with cardiovascular and metabolic risk much more than the SAT. 4 The VAT exerts predominantly systemic effects, while the EAT mostly exerts local effects in the heart. Here, the EAT is mainly located in the atrioventricular and interventricular grooves, in close active in the release of FFAs and proinflammatory molecules.
Since the EAT and the VAT share the same embryological origin, 11 the EAT can be considered as the visceral fat depot of the heart. 12 In physiological conditions, the EAT represents a substantial fractionabout 20%-of the heart weight. Most of the EAT is in the atrioventricular and interventricular grooves, and over the free wall of the right ventricle. 12 Minor foci of EAT are also located along the free walls of the atria, around the atrial appendages and the myocardium, usually around the branches of a coronary artery. 13 It is worth noting that no other tissue separates the EAT from the myocardium and the Figure 1 Morphological and functional heterogeneity of the AT. Body fat is stored as white adipose tissue (WAT), brown-in-white (brite) AT, and brown adipose tissue (BAT). White adipocytes are spherical, and their cytoplasm is filled with a single large lipid droplet with few mitochondria. Brown adipocytes exhibit a more polygonal shape and numerous small lipid droplets, giving them a multi-locular appearance; they are smaller in size than white adipocytes, contain a larger number of mitochondria and a central nucleus. Brite adipocytes show intermediate characteristics. These depots differ in histology, body location, function and impact on obesity, and atherogenesis. Black: nucleus, red: mitochondria, yellow: lipid droplets. CAD, coronary artery disease; UCP, uncoupling protein.
coronary arteries, so that the latters perfuse both the myocardium and the EAT. 12 
Physiology
In normal physiological conditions, the EAT exerts several essential functions, both for survival and cardiovascular activities. Metabolically, the EAT features high rates of lipogenesis and lipolysis, typical of the WAT. 14 In adult guinea pigs, the rate of fatty acids synthesis, release and breakdown in response to catecholamines has been reported to be higher than that of other adipose depots. 14 Therefore, a first potential function of the EAT is that it can act as a buffering system against toxic plasma levels of fatty acids. 14 On the other hand, the high lipolytic activity of the EAT suggests that it can serve as a source of local energy, by providing FFAs to meet the higher energy demands of the myocardium in ischaemic conditions. 15 The ability to rapidly synthesize and metabolize FFAs is vital, since, in humans, FFAs are the primary fuel of the myocardium. 16 Surrounding the coronary arteries, the EAT also exerts a supportive mechanical function, attenuating vascular tension and torsion, and providing mechanical protection during cardiac contraction. 17 Furthermore, the EAT modulates coronary vascular tone, by secreting several vasoactive factors, such as leptin, 18 adiponectin, 19 nitric oxide, 20 omentin-1, 21 and adrenomedullin. 22 Finally, expressing markers typical of the brown fat, such as uncoupling protein (UCP)-1 and PR domain containing 16 (PRDM16), 23 the EAT also has thermogenic properties that allow to adapt its functions-in a manner similar to the BAT-to protect the myocardium and the coronary arteries under hypothermic conditions. 24 This has been recently confirmed in humans by histological and transcriptional studies, documenting that the EAT is phenotypically brown during the early stages of life 25 and, despite whitening with age, 25 maintains brown/beige characteristics in adulthood. 23 However, in cardiovascular patients there is evidence for an accelerated brown-to-white transdifferentiation. This is evidenced by a significant decrease in the expression of brown fat-like genes, such as peroxisome proliferatoractivated receptor gamma coactivator 1-alpha (PGC-1a), UCP-1, and PRDM16
26
; and increased expression of white fat-like genes, including the insulin-like growth factor binding protein (IGFBP)3 and homeobox (HOX)C8 and 9 26 ( Figure 1 ). This whitening process has been associated with significantly increased production of reactive oxygen species 26 and the expression of proinflammatory genes 27 by the EAT, and is accompanied by a reduction in plasma fatty acids clearance. 28 Therefore, it has been hypothesized that EAT whitening and the subsequent locally occurring AT dysfunction may lead to an inflammatory microenvironment affecting vascular homeostasis and possibly triggering coronary atherosclerosis. 25 In support of this hypothesis, it has recently been observed that b-adrenergic receptor stimulation of the BAT in a mouse model of atherosclerosis translates into a significant amelioration of hyperlipidaemia and protection from atherosclerosis. 29 However, whether the loss of thermogenic properties of the EAT under obesogenic conditions represents the prevailing mechanistic link between EAT and the development of coronary atherosclerosis still needs to be better documented in humans. 30 Nevertheless, the value of carotid IMT by ultrasound examination for risk stratification remains controversial. 31 and, in accordance with the latest guidelines on cardiovascular prevention, no longer recommended for risk assessment because of lack of standardization in definition and measurement, as well as high between-and withinindividual variability. 32 On the contrary, the EAT volume correlates with imaging biomarkers, such as coronary artery calcium (CAC) score, that in turn correlates with the extent of total coronary plaque burden. 33 and is a well-recognized predictor of CAD. 32 In symptomatic and asymptomatic patients, the EAT volume is associated with the presence, extension, and progression of CAC and with histological features of high-risk plaques. [34] [35] [36] [37] In the Framingham Heart cohort, involving 3217 participants, the EAT volume, quantified by CT, is positively associated with CAC, even after adjusting for other CAD risk factors and global measures of adiposity, such as the body mass index (BMI). 38 This observation has been further confirmed in other studies, such as the Multi-Ethnic Study of Atherosclerosis (MESA) study, involving 159 patients without evidence of CAD 36 and in the CArdiometabolic risk, Epicardial fat, and Subclinical Atherosclerosis Registry (CAESAR), 39 enrolling 2299 individuals at high risk, where the EAT volume is positively associated with both the presence and the extent of calcified coronary artery plaques, even adjusting for other CAD risk factors. Thus, the EAT volume is an independent predictor of CAC and early CAD, 40 with better prediction of CAD than simple anthropometric measures. There is also a close relationship between the EAT volume and the presence of 'soft' or 'mixed' plaques with characteristics of high vulnerability, associated with negative outcomes. 40 A recent meta-analysis of nine observational studies including 3772 patients with suspected CAD and undergoing either intracoronary imaging or CT coronary angiography, showed the association of high-risk atherosclerotic plaques and increased EAT as measured by volumetric assessment, but not by the assessment of linear thickness, suggesting the importance of a proper measurement method to investigate such associations. 41 In addition, the EAT thickness has been shown to have no incremental diagnostic value in addition to the CAC score for detecting haemodynamic significant coronary stenosis as assessed by the invasive fractional flow reserve (FFR). 42 Recent evidence has also shown the existence of a sex-specific relationship of the EAT volume with the Epicardial adipose tissue and coronary artery disease polycystic ovary syndrome in women. This is a common endocrine disorder that affects 5-10% of women in the reproductive age, characterized by hyperandrogenism, menstrual disturbances, chronic anovulation, and infertility. 43 Such syndrome is associated with increased cardiovascular risk and early atherosclerosis. Other studies have also shown that the EAT volume is higher in post-menopausal women with the metabolic syndrome. These findings would imply that the echocardiographic evaluation of the EAT volume might be a simple and reliable indicator of cardiovascular risk in men and women. 44 Taken together, these clinical studies suggest the EAT volume as a biomarker of subclinical atherosclerosis, independent of other CAD risk factors. EAT volume might thus be used to assess-and possibly monitor-the risk of developing cardiovascular disease, 45 help stratify symptomatic patients who might benefit from a closer follow-up, identify better therapeutic targets, and monitor weight loss interventions in patients with cardiometabolic disease.
Clinical evidence of a relationship between EAT and CAD
A new approach for assessing coronary inflammation and subclinical CAD (soft, non-calcified plaques) involves the evaluation of perivascular adipose tissue (PVAT) surrounding the coronary arteries using the perivascular CT attenuation index (FAI). 46 The perivascular FAI uses PVAT CT imaging to evaluate adipocyte size and lipid content and relies on the principle that PVAT attenuation measured by CT can change around highly inflamed regions such as ruptured plaques 47 or spontaneous coronary dissections. 48 Thus, FAI can detect coronary inflammation by characterizing changes in CT attenuation of peri-coronary AT. 46 In a recent research work, Antonopoulos and co-workers have shown that the FAI is able to detect the degree of coronary artery inflammation, can discriminate between ruptured and non-ruptured coronary atherosclerotic plaques in acute coronary syndromes, and may provide data on coronary atherosclerotic plaque burden independent of coronary calcium scoring. 46, 49 An additional approach for assessing and risk stratifying atherosclerotic plaque is hybrid positron emission tomography/CT (PET/CT), using CT for the identification and localization of PVAT and PET measurement of the glucose analogue 2-[18F]fluoro-2-deoxyglucose (FDG) uptake in this pre-determined anatomic location (PET). FDG is taken up by highly glycolytic macrophages through GLUT 1/3 transporters and has also shown strong correlation with other inflammatory markers. 50 Therefore, FDG PET imaging can provide a focal inflammation index in atherosclerotic plaques and is thought to provide an index of plaque instability. 50 The highest inflammation in PVAT shown by PET/CT was correlated with atherosclerotic plaque development as shown by coronary angiography. 51 PVAT has been also investigated in relation to cardiovascular risk factors and EAT volume using PET/CT. 52 CT-measured attenuation of PVAT was influenced by the amount of EAT and the point along the vascular lumen, as PVAT volume and density appeared to change from distal to proximal segments of the coronary arteries. 52 Nevertheless, the identification and localization of PVAT with CT is a fairly new technique that is still under investigation, and the optimal methodology for obtaining reproducible and reliable results has not yet been established. The abundance (volume) of EAT has also been associated with myocardial perfusion abnormalities, as assessed by myocardial CT perfusion imaging, 53 with functional coronary stenoses as invasively assessed by the FFR, 53 with symptomatic coronary vasospasm (vasospastic angina) during acetylcholine provocative testing in patients with asymptomatic coronary artery vasospasm, 54 quantified by non-contrast electrocardiogram (ECG)-gated CT during ergonovine-induced coronary spasm. 55 Only in two additional studies the EAT thickness has been associated with symptomatic coronary vasospasm during acetylcholine provocative testing. 56, 57 Furthermore, the EAT thickness has been found associated with infarct-related artery patency before mechanical reperfusion in patients with ST-segment elevation myocardial infarction (STEMI), and is an independent predictor of lower Thrombolysis in Myocardial Infarction (TIMI) flow grade in the infarct-related artery in these patients. 58 
The EAT and CAD: possible causal relationship
There are several pathophysiological processes potentially linking EAT and CAD. The first hypothesis of a causal role of the EAT in the development of coronary atherosclerosis was formulated in 1950 by Burnsides et al. 59 These authors observed that atherosclerotic lesions were preferentially localized in coronary arteries surrounded by AT, whereas intramural segments were generally spared. Subsequently, this observation was confirmed and complemented by the finding that intramyocardial segments of coronary arteries are largely unaffected by atherosclerosis. 60 This focal distribution of atherosclerosis was associated with evidence of inflammation in the EAT and increased expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a main receptor for oxidized LDL (OxLDL), in the arterial wall of epicardial coronary arteries compared with intramyocardial coronary arteries. 61 Correspondently, it was shown that conditioned media (CM) from human EAT increase the endothelial permeability to LDL, 62 thus demonstrating a functional mechanism causally linking the EAT to cholesterol accumulation in atherosclerotic plaques. 5 Moreover, the EAT collected at cardiac surgery from patients with severe CAD was shown to contain a greater number of inflammatory cells and a higher expression of inflammatory cytokines than subcutaneous fat. 63 These proinflammatory properties were apparently independent of plasma concentration of circulating biomarkers, as well as of clinical variables, such as diabetes, the BMI and chronic statin intake. 63 Compared with patients without CAD, those with CAD also exhibited lower levels of the atheroprotective cytokine adiponectin in the EAT, and these levels seemed to correlate inversely with increased complexity of coronary atherosclerotic lesions. 64 A dysfunction or excess of epicardial (peri-coronary) AT is thought to directly induce inflammation of adjacent arteries and thus contribute to the pathogenesis of atherosclerosis, plaque rupture, and thrombosis. [65] [66] [67] Hypoxic and dysfunctional changes of the EAT indeed result in lipolytic and inflammatory activities through a dysregulated local secretion of vasoactive and inflammatory factors, known to participate in several stages of atherosclerosis, including changes in vascular tone and vascular remodelling, chemotaxis, foam cell formation, smooth muscle cell proliferation and migration, as well as plaque destabilization. The activity of metalloproteinase 2 and 9 has been shown to be highly increased in the EAT of patients with CAD, thus potentially sustaining the extracellular matrix remodelling and the increased vascular density necessary for both EAT expansion and plaque destabilization. 68 The EAT can directly contribute to atherosclerosis also through an 'outside-to-inside' inflammatory atherogenic signal, conveyed through the vasa vasorum. 13, 69 The short distance between the EAT and the coronary artery wall can allow paracrine signalling by direct diffusion of proinflammatory cytokines, such as interleukin (IL) 1, IL-6, IL-8, monocyte chemoattractant protein 1, leptin, plasminogen activator inhibitor-1, resistin, RANTES, and tumour necrosis factor a, and other adipokines, some of which also with potentially protective factors, into the vessel wall and the coronary circulation, to exert their pathophysiological effects. 65 71 show a dysregulated expression and release of these factors by the EAT, with enhanced potential to induce atherogenic changes in monocytes and endothelial cells. In vitro studies using human adipocyte-endothelial cell co-culture systems support the potential paracrine effects of adipocytes on endothelial cells with relevance to inflammation and atherosclerosis. Endothelial cells incubated with adipocyte-CM display increased monocyte adhesion via up-regulation of adhesion molecules, 72 and increased proinflammatory cytokine/chemokine secretion. 73 Hypoxia and inflammation have also been shown to enhance the proinflammatory profile and the endothelial activating capacity of pre-adipocytes and adipocytes. 73 However, these studies have used adipocytes isolated from VAT or SAT samples mainly to address obesityrelated vascular complications. Due to the close proximity to the myocardium, EAT also acts as a metabolic transducer for various mediators leading to a paracrine crosstalk with the myocardium. 74, 75 Through this paracrine activity, cytokines from the EAT could diffuse directly across the interstitial fluid into the myocardium or into arterial wall layers to finally interact downstream with the myocardium. 3 Alternatively, cytokines from the EAT may be directly released into the vasa vasorum of the coronary arterial wall. 69 Most recent studies have highlighted the role of extracellular vesicles, such as exosomes, in the exchange of proteins, lipids, and microRNAs between the EAT, coronary arterial wall, and myocardium, and viceversa. 76 The extent of interaction between EAT-derived microparticles and surrounding cells is still unclear, but experimental studies have led to the hypothesis that these particles can promote migration and infiltration of monocytes and proinflammatory cells. 77 In particular, endothelial microparticles containing miR-19b have been shown to accelerate atherosclerosis and promote EAT inflammation in apoE -/-mice. 78 Recently a role of the pericardial AT has been described in the inflammatory response after a myocardial infarction. 79 Here, the pericardial AT has been shown to contain a high density of lymphoid clusters with B cells, dendritic cells, and T cells that expand in response to myocardial injury and release cytokines and growth factors locally and systemically, thus promoting granulopoiesis and scar formation after the infarction. Therefore, the pericardial AT plays a key role in regulating postmyocardial infarction healing through the induction of innate and adaptive immune responses. 79 CM of EAT from patients with type 2 diabetes also showed an enhanced potential to induce contractile dysfunction, mainly due to high content of activin A and angiopoietin-2, through a down-regulation of sarcoplasmic reticulum ATPase 2a. 71 Another example of bi-directional cross-talk between the EAT and the myocardium derives from the observation that human EAT accumulates in the atrial myocardium due to the release-by atrial cardiomyocytes-of atrial natriuretic peptide, which induces an adipogenic differentiation of multipotent mesenchymal epicardium-derived cells. In turn, the EAT can promote fibrosis of the neighbouring atrial myocardium by secreting cytokines such as activin A 80 or by favouring fibrosis of the atrial subepicardium, 81 thus influencing atrial mechanical function. 82 
Molecular signatures of the EAT
The definition of specific molecular characteristics of the EAT (molecular signatures) in coronary patients by high-throughput screening may be helpful for an unbiased understanding of pathogenic mechanisms that link the EAT with coronary atherosclerosis, as well as in identifying expressions and activities of the EAT genes that may serve as potential new targets for treatment and/or prevention of coronary atherosclerosis. By combining whole-genome transcriptomic analysis and related bionformatic evaluations, several research groups have characterized the prevailing activated pathways and sets of genes in the transcriptome of the EAT derived from cardiovascular patients. A recent meta-analysis of observational studies focused on the transcriptomic evaluation of human EAT from coronary patients has confirmed the prevailing activation of inflammatory, immunological and metabolic pathways in diseased EAT 83 and highlighted a now-recognized role for interleukin (IL)-6 and tumour protein p53 (TP53) as main core/hub genes. 83 These results confirm the potential key role played by local inflammation and apoptosis in mediating the development of cardiovascular disease. 84 However, new unsuspected, but potentially relevant genes also begin to be frequently noted. This new list of dysregulated genes in the EAT include, among others, in an increased expression, phospholipase A 2 type II (sPLA 2 -IIA), adenosine A1 Receptor (ADORA1), prostaglandin D 2 synthase (PTGDS), and arachidonate 15-lipoxygenase (ALOX15) ( Table 2) . It is interesting to note that the first miRNome profiling of the human EAT has produced complementary results in terms of involvement of proinflammatory and proapoptotic pathways, and of the 'whitening' processes. By performing transcriptomic and miRNome analysis on the EAT and the SAT obtained from coronary patients, the dysregulation of several inflammatory-related miRNAs, including the up-regulation of miR-135b-3p, 85 and the downregulation of let-7a-3p and miR-127-3p 83 has been recently recognized.
Furthermore, a clear suppression of miR-455-3p, a driver of brown adipocyte differentiation, 86 has also been found ( Figure 2) . Definitive conclusions cannot yet, however, be drawn, since a rigorous comparative analysis is made difficult by the often underpowered sample sizes and the nonhomogeneity of fat tissue used as control (e.g. SAT from the same individual instead of EAT from non-cardiovascular valvular patients, see Table 2 ).
Nonetheless, overall, these results are enlightening, since they suggest pathways useful to identify new potential mechanisms underlying coronary atherosclerosis under obesogenic conditions and to open new paths for investigation.
Imaging methods for the quantification of EAT-relative pros and cons
EAT quantification may be relatively easily done by a variety of different imaging techniques. Two-dimensional transthoracic echocardiography (TTE) is the most accessible and safe procedure for EAT assessment. 87 Although limited to the EAT surrounding the right ventricle, results from TTE examination are strongly related to those achieved with MRI. 88 Furthermore, a value >5 mm has been suggested as the threshold to define 'increased' EAT thickness in low-risk populations, 89 whereas there is no consensus for a threshold in obese subjects. [90] [91] [92] Although ultrasound remain the most readily available, safe and low-cost technique to measure EAT abundance, echocardiographic determination of EAT remains biased by the low reproducibility, has an inbred operator-dependence, and is unable to probe all locations of the EAT. Some recommendations should be taken into account during echocardiographic measurement of the EAT, such as repetition of the measurement in at least 3 (with some authors recommending 6 or even 10) cardiac cycles. 93 For this reason, CT and MRI, which were initially used as complementary to echocardiography, are now gaining a prominent position by virtue of their reproducibility, high spatial resolution and volumetric quantification. Cardiac magnetic resonance (CMR) is currently considered the gold standard for EAT quantification. 94, 95 Both thickness and volume can be easily measured by CMR. 96 Nevertheless, the high costs and the high time expenditure for the procedure are still limiting its routine use in clinical practice. Finally, CT provides the best sensitive and accurate EAT assessment due to the higher spatial resolution as compared with ultrasound and CMR. 97 Regional EAT thickness and volume may be assessed and potentially correlated with coronary calcium score and degree of stenosis. 98 Three-dimensional images may be reconstructed with multidetector-row CT (MDCT), further improving spatial resolution. Although this technique is burdened by the exposure to ionizing radiation and high costs, cardiac CT is probably the best suitable tool for clinical studies. 99 
Conclusions, gaps in knowledge, open questions, and translational perspectives
The EAT is the true visceral AT of the heart, playing an important pathogenic role in the development of CAD. The EAT volume is to be considered a strong potential predictor of CAD, although cut-off values for the EAT thickness in predicting cardiovascular risk have not yet been welldefined in obese patients. Nevertheless, researchers have identified a threshold that could characterize high-risk populations for CVD 5 ( Table 2) . Cardiac CT and CMR easily detect and quantify EAT volume and thickness precisely and completely, but ultrasound remain the most readily available, safe and low-cost technique. Limitations here are the operator dependency, and the poor capability to probe all locations of the EAT. The EAT abundance measured by echocardiography, MRI, and PET/CT can play a role as a biomarker of early atherosclerotic CAD. Furthermore, EAT assessment might help stratify symptomatic patients who might benefit from a closer follow-up, identify better therapeutic targets, and also monitor weight loss interventions in patients with cardiometabolic disease. A critical aspect in the near future will be the evaluation of the incremental predictive value of EAT over established cardiovascular risk factors, as well as the introduction of EAT in clinical practice for effective risk stratification and the prevention of coronary thrombotic events. Further studies are needed to determine the limit values for EAT thickness, able to distinguish normal from high-risk patients, and whether changes in EAT thickness correlate with changes in risk. The isolation of EAT samples during Coronary Artery Bypass Grafting interventions should be encouraged, with the aim to characterize the activation of specific transcriptomic profiles that might be useful to a better definition of patients' risk profile. Seminal results are already available ( Table 2) , but the procedures for analysis need to be standardized and results confirmed in large population studies. More importantly, however, the uncovering of specific mechanisms by which the EAT might causally promote CAD might contribute to reveal new important therapeutic targets for cardiovascular therapy and explain unsolved issues on local factors favouring atherosclerosis.
